Jonathan Allan Biography and Net Worth

General Counsel of Stoke Therapeutics

Jonathan Allan, J.D., is the general counsel at Stoke Therapeutics. In his role, Jonathan oversees all aspects of legal, including providing leadership and guidance on all legal and compliance initiatives and serving as Compliance Officer and Corporate Secretary to Stoke’s Board of Directors.

Jonathan has built his career providing legal support and counsel to life science and technology companies at various stages of growth and brings particular expertise in the areas of corporate governance, securities and public company reporting, corporate transactions, employment matters and intellectual property. Before joining Stoke, Jonathan was an associate in the corporate group at Fenwick & West LLP, providing legal support to some of the world’s most innovative technology and life sciences companies. Prior to that, he served as a corporate associate at Kirkland & Ellis LLP, where he advised a number of public and private clients in shareholder matters and corporate transactions.

Jonathan is a member of the New York Bar Association. He holds his J.D. from The Ohio State University Moritz College of Law and a B.A. in business administration and marketing from Grace College.

What is Jonathan Allan's net worth?: The estimated net worth of Jonathan Allan is at least $608.95 thousand as of December 3rd, 2025. Mr. Allan owns 19,612 shares of Stoke Therapeutics stock worth more than $608,953 as of December 5th. This net worth approximation does not reflect any other assets that Mr. Allan may own. Learn More about Jonathan Allan's net worth.
How old is Jonathan Allan?: Mr. Allan is currently 34 years old. There are 7 older executives and no younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics is Dr. Edward M. Kaye M.D., Ph.D., CEO & Director, who is 75 years old. Learn More on Jonathan Allan's age.
How do I contact Jonathan Allan?: The corporate mailing address for Mr. Allan and other Stoke Therapeutics executives is 45 WIGGINS AVENUE, BEDFORD MA, 01730. Stoke Therapeutics can also be reached via phone at (781) 430-8200 and via email at [email protected]. Learn More on Jonathan Allan's contact information.
Has Jonathan Allan been buying or selling shares of Stoke Therapeutics?: In the last ninety days, Jonathan Allan has sold $388,967.32 in Stoke Therapeutics stock. Most recently, Jonathan Allan sold 2,292 shares of the business's stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $30.65, for a transaction totalling $70,249.80. Following the completion of the sale, the general counsel now directly owns 19,612 shares of the company's stock, valued at $601,107.80. Learn More on Jonathan Allan's trading history.
Who are Stoke Therapeutics' active insiders?: Stoke Therapeutics' insider roster includes Jonathan Allan (General Counsel), Edward Kaye (), Edward Kaye (Director), Huw Nash (COO), and Barry Ticho (Insider). Learn More on Stoke Therapeutics' active insiders.
Are insiders buying or selling shares of Stoke Therapeutics?: In the last twelve months, insiders at the sold shares 31 times. They sold a total of 319,912 shares worth more than $6,612,569.40. The most recent insider tranaction occured on December, 3rd when insider Barry Ticho sold 2,014 shares worth more than $61,729.10. Insiders at Stoke Therapeutics own 9.5% of the company. Learn More about insider trades at Stoke Therapeutics.
Information on this page was last updated on 12/3/2025.

Jonathan Allan Insider Trading History at Stoke Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/3/2025	Sell	2,292	$30.65	$70,249.80	19,612
12/2/2025	Sell	2,284	$29.78	$68,017.52	21,904
10/3/2025	Sell	10,000	$25.07	$250,700.00	11,831
9/3/2025	Sell	6,345	$20.07	$127,344.15	11,831
9/2/2025	Sell	14,922	$20.14	$300,529.08	18,176
8/29/2025	Sell	850	$20.00	$17,000.00	23,948
8/13/2025	Sell	13,712	$15.00	$205,680.00	19,631
3/18/2025	Sell	2,266	$8.67	$19,646.22	33,510
12/9/2024	Sell	13,666	$13.61	$185,994.26	21,476
12/6/2024	Sell	9,696	$12.78	$123,914.88	35,142
3/28/2024	Sell	5,126	$13.20	$67,663.20	2,598
3/19/2024	Sell	2,349	$6.10	$14,328.90	7,724
6/21/2023	Sell	1,948	$13.48	$26,259.04

Jonathan Allan Buying and Selling Activity at Stoke Therapeutics

Stoke Therapeutics Company Overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $31.05

$30.10

$31.54

50 Day Range

MA: $28.90

$22.37

$35.60

2 Week Range

Now: $31.05

$5.35

$38.69

Volume

659,414 shs

Average Volume

951,880 shs

Market Capitalization

$1.77 billion

P/E Ratio

46.34

Dividend Yield

N/A

Beta

1.14

Jonathan Allan Biography and Net Worth

What is Jonathan Allan's net worth?

How old is Jonathan Allan?

How do I contact Jonathan Allan?

Has Jonathan Allan been buying or selling shares of Stoke Therapeutics?

Who are Stoke Therapeutics' active insiders?

Are insiders buying or selling shares of Stoke Therapeutics?